Chiasma is a clinical-stage biopharmaceutical company dedicated to addressing the everyday challenges associated with existing therapies for rare or serious chronic diseases.
Location: United States, Massachusetts, Waltham
Total raised: $164.5M
Investors 4
| Date | Name | Website |
| - | XT Hi-Tech | xthitech.c... |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | Sofinnova ... | sofinnova.... |
| - | Abingworth... | abingworth... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 27.02.2015 | Series E | $70M | - |
| 29.12.2014 | - | $56M | - |
| 23.07.2012 | Series D | $38.5M | - |
Mentions in press and media 9
| Date | Title | Description |
| 26.07.2019 | Chiasma Announces Pricing Of Underwritten Public Offering Of $55.0 Million Of Common Stock | - |
| 04.10.2016 | Samsung BioEpis pitches Herceptin biosimilar as parent company hunts $2B IPO; Chiasma CEO is out | In the latest advance by a new wave of biosimilars hitting regulators on both sides of the Atlantic, Samsung Bioepis says that it has filed for a European approval of a knockoff of Herceptin. Bioepis is majority controlle... |
| 02.03.2015 | Chiasma Completes $70M Series E | NEWTON, MA, Privately-held biopharma company developing octreotide capsules, its lead product for the orphan condition acromegaly, today announced the closing of a $70 million Series E financing round. >> Click here for more fundin... |
| 27.02.2015 | Chiasma Announces Completion of $70 Million Series E Financing | - |
| 27.02.2015 | Chiasma Closes $70M Series E Financing Round | Chiasma, Inc., a U.S. privately-held biopharma company, closed a $70m Series E financing round. Backers included new investors Rock Springs Capital and Sofinnova Ventures, and an undisclosed blue chip public investment fund, as well as exis... |
| 02.01.2015 | With Roche out the door, Chiasma is raising $56M to go it alone | In early 2013, Roche ($RHHBY) signed a $595 million deal with Israel's Chiasma with eyes on its promising treatment for the hormone disorder acromegaly. But the Swiss drugmaker got cold feet over the summer, and now Chiasma is picking up th... |
| 29.12.2014 | Despite Roche dropping $595M deal, Israeli startup Chiasma raises $33.8M for acromegaly drug | Roche initially held a $595 million commercialization deal with Chiasma, but cancelled it this August, according to Israeli business publication Globes. It writes: In a conference call, Roche explained that in view of its 1st half results, ... |
| 23.07.2012 | Chiasma Closes $38.5M Series D Equity Financing | Chiasma, Inc., a Jerusalem, Israel-based biopharma company, has closed a $38.5m Series D equity financing. The round was co-led by new investor Abingworth and existing investor MPM Capital, with participation from existing shareholders 7 Me... |
| - | Despite Roche dropping $595M deal, Israeli startup Chiasma raises $33.8M for acromegaly drug | Israeli startup Chiasma in the midst of a hefty fundraise: It’s raised $33.8 million of a proposed $56.3 million round, according to regulatory filings. This comes as a timely vote of confidence – the company was expecting a $595 million de... |